6月1日，药明合联盘中上涨3.1%，报55.6港元/股，成交额4129.77万港元，延续此前反弹走势。
消息面上，公司此前披露专业受托人于5月19日至29日期间在公开市场购买570.2万股，总代价约3.27亿港元，平均购买价每股57.3港元，资金全部来自公司自有财务资源。叠加母公司药明生物不超过4亿美元回购计划，药明系合计回购规模达5亿美元。国泰海通维持公司"增持"评级，目标价84.38港元，看好ADC赛道增长前景。板块内药明生物今日涨5.94%，整体情绪明显回暖。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.